Bristol-Myers Squibb Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMY research report →
Range $41 – $78
Price Chart
About the company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism.
- CEO
- Christopher Boerner
- IPO
- 1972
- Employees
- 32,500
- HQ
- Princeton, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a multi-month recovery but remains below its 200-day average, so the longer-term trend is not fully repaired. It sits well off the 52-week high and closer to the middle of its yearly range, which keeps the setup constructive but not yet decisive.
Street sentiment is cautious-to-neutral, with a Hold consensus and a $66.14 median target versus a $58.81 share price. Recent changes lean mixed: several firms kept neutral stances, while target moves ranged from $41 to $78, showing conviction is present but not uniform.
BMY has a strong beat streak, with 8 straight EPS beats and the last four surprises ranging from 5.0% to 28.3%. Next-year EPS is modeled at $6.70 versus $4.51 TTM, so shareholders should watch whether pipeline execution and margin discipline keep that upgrade path intact.
The pattern is net selling, but most of the activity is automatic vesting, exemption, or in-kind tax-related flow rather than open-market conviction. The only clear discretionary sale was a director sale of 3,800 shares, while recent officer transactions were dominated by M and F codes.
Profitability is solid, with a 70.5% gross margin, 32.4% operating margin, and 18.5% net margin. Cash generation is strong at $15.47 billion of free cash flow and a 12.97% FCF yield, but leverage remains meaningful with $47.14 billion of debt against $10.67 billion of cash.
BMY screens as a cash-generative large-cap pharma name with a lower-beta profile and a valuation that is not demanding at 9.84x earnings. The setup favors investors who want defensive earnings power and pipeline optionality rather than high-growth biotech exposure.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $120.19B
- P/E
- 13.02
- Fwd P/E
- 9.11
- PEG
- 0.25
- P/S
- 2.40
- P/B
- 5.14
- EV/EBITDA
- 10.26
- Div Yield
- 4.28%
- Gross Margin
- 69.24%
- Op Margin
- 26.07%
- Net Margin
- 18.47%
- ROE
- 43.88%
- ROIC
- 14.89%
Latest fiscal year · YoY change
- Revenue
- $48.20B-0.2%
- Gross Profit
- $34.26B-0.2%
- Op Income
- $13.72B
- Net Income
- $7.05B+178.8%
- EPS
- $3.46+178.5%
- OCF Growth
- -6.8%
- FCF Growth
- -7.9%
- 52W High
- $68.64
- 52W Low
- $45.52
- 50D MA
- $61.55
- 200D MA
- $60.43
- Beta
- 0.23
- RSI (14)
- 37
- Avg Volume
- 11.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bristol Myers Squibb delivered a solid Q3 with 7% revenue growth, 12% growth-portfolio growth, and raised full-year guidance on the strength of Eliquis and a broadening pipeline.· October 29, 2026
- Total Q3 revenue rose 7% year over year to $13.1 billion, with growth-portfolio sales up 12% to $7.7 billion.
- Eliquis remained a major driver, rising 26% to $4.7 billion, while Qvantig, Reblozyl, Breyanzi, Camzyos, Sotyktu and Cobenfy all posted growth.
- Management said the pipeline had four positive registrational readouts in two months, including Symvexis PFS data, admilparant in IPF, RAISE 101 in GEP-NETs, and Arlocell in myeloma.
- Full-year guidance was raised; 2026 non-GAAP EPS is now expected at $6.35 to $6.55, and legacy-portfolio revenue is now expected to decline 3% to 5%.
- The company reiterated multiple upcoming catalysts in late 2026 and 2027, including Milvexian in stroke and AFib, Sotyktu in lupus, and the ADEPT Alzheimer’s program.
Q3 2026 total revenue increased 7% year over year to $13.1 billion. Growth portfolio revenue rose 12% to $7.7 billion, while legacy portfolio revenue increased 1%. Gross margin was 68.4%, operating expenses were $4.1 billion, and diluted EPS was $1.35. Eliquis revenue was $4.7 billion, up 26%; Opdivo was $2.4 billion, down 6%; Qvantig was $334 million, up sequentially 28%; Reblozyl grew 22% to $750 million; Breyanzi grew 48% to $526 million; Camzyos grew 42% to $420 million; Sotyktu grew 25%; and Cobenfy grew 33% to $57 million. Cash equivalents and marketable securities were approximately $13 billion as of September 30, and operating cash flow was approximately $4.2 billion in the quarter. For 2026, non-GAAP EPS guidance is now $6.35 to $6.55, with gross margin, operating expenses, and tax rate maintained, other income/expense slightly lower, and legacy-portfolio revenue expected to decline 3% to 5%. The company still expects Eliquis full-year revenue growth of 20% to 25%.
Christopher Boerner said the quarter showed a company with 'real momentum,' highlighting double-digit growth in the growth portfolio, progress de-risking the pipeline, and multiple positive clinical/regulatory milestones. He stressed that BMS is building toward long-term durable growth by executing commercially, advancing late-stage assets, and staying disciplined on costs and capital allocation. He also framed 2027 and beyond as a period where the company will translate pipeline progress into launches while continuing to improve operating efficiency and productivity.
David Elkins emphasized continued strong execution, especially from the growth portfolio and Eliquis, and said the company is further raising full-year guidance. He pointed to the 68.4% gross margin, $4.1 billion of operating expenses, $1.35 diluted EPS, about $13 billion in cash and marketable securities, and about $4.2 billion in quarterly operating cash flow. He also noted the company remains focused on balancing investment with productivity, maintaining the dividend, and evaluating business development opportunities, while citing a $0.58 per share impact from acquired in-process R&D and licensing income in the quarter.
Analysts focused on admilparant, Milvexian, Cobenfy, Qvantig conversion, the ADEPT Alzheimer’s program, RayzeBio/RAISE 101, and autoimmune CAR-T Zolacel. Management said admilparant met its primary endpoint at the 60 mg dose with a favorable safety profile, but the 120 mg dose was not statistically significant and the team will continue to analyze the data and meet with regulators. On Milvexian, management reiterated confidence in the upcoming stroke and AFib readouts, said the AFib press release would aim to give a useful read on the outcome, and noted they are balancing detail with later medical-conference disclosure. On Cobenfy and Qvantig, management said launch adoption and physician feedback have been positive, though Cobenfy still needs more new-patient starts and more patients on the 125 mg dose; Qvantig conversion is roughly 17% of IV-to-subcu launch to date, with a target of 30% to 40% conversion over time.
The bullish case is that BMS is showing broad-based commercial momentum, with 8 growth-portfolio medicines now annualizing at more than $1 billion and multiple brands growing strongly. The pipeline also appears to be delivering across several modalities, and management sounded confident about upcoming data readouts and the company’s ability to turn them into launches.
The main risks are the looming Eliquis LOE in Europe and the broader revenue gap that management still expects in 2027, including a $1.5 billion to $2 billion Eliquis step-down. Several programs still have meaningful execution and readout risk, including Milvexian, the remaining ADEPT studies, Cobenfy adoption, and the need to convert early clinical wins like admilparant and RAISE 101 into regulatory and commercial success.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 2.04B
- Float Shares
- 2.04B
of shares held by institutions
2,636 13F filers
Buy/sell ratio 0.55. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BMY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Apr 15, 25 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Mike KellyHouse · PA16 | Sell | May 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Dec 18, 25 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Apr 28, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 19, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 12, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Nov 13, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 9, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 29, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 198.73M | ▲ 2.74M |
| Blackrock, Inc. | 173.66M | ▼ 6.72M |
| Vanguard Capital Management LLC | 133.69M | ▲ 347.32K |
| State Street Corp | 103.34M | ▲ 926.68K |
| Charles Schwab Investment Management Inc | 72.45M | ▲ 4.86M |
| Jpmorgan Chase & Co | 60.22M | ▼ 11.50M |
| Geode Capital Management, LLC | 50.64M | ▼ 5.80M |
| Vanguard Portfolio Management LLC | 47.06M | ▲ 188.96K |
| Bank Of America Corp | 40.28M | ▲ 6.23M |
| Norges Bank | 36.87M | ▲ 36.87M |
| Morgan Stanley | 28.38M | ▼ 629.28K |
| Fmr LLC | 28.32M | ▲ 12.02M |
Held by 2,706 ETFs
Biggest fund positions in BMY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 5, 26 | Haller Julia A | sell | 3,800 |
| Nov 3, 26 | Lenkowsky Adam | other | 7,522 |
| Nov 3, 26 | Lenkowsky Adam | other | 3,848 |
| Nov 3, 26 | Lenkowsky Adam | other | 7,522 |
| Nov 1, 26 | BOERNER CHRISTOPHER S. | other | 406 |
| Nov 1, 26 | BOERNER CHRISTOPHER S. | other | 2,964 |
| Nov 1, 26 | BOERNER CHRISTOPHER S. | other | 1,724 |
| Nov 1, 26 | BOERNER CHRISTOPHER S. | other | 2,964 |
| Nov 1, 26 | Shanahan Karin | other | 6,281 |
| Nov 1, 26 | Shanahan Karin | other | 3,213 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BMY coverage
Recent articles, reports, and earnings notes.

Bristol-Myers Squibb (BMY): Cash Flow and Growth Portfolio Support
Bristol-Myers Squibb combines strong cash generation with a broadening growth portfolio, but legacy-product dependence and debt keep the story balanced. The stock looks attractive on valuation, with Eliquis and newer launches helping offset patent pressure.

Bristol-Myers Squibb Company (BMY) Gains After Deep Q3 Earnings
Bristol-Myers Squibb Company (BMY) gains after a deep Q3 earnings review showing beats on EPS and revenue, stronger growth-brand sales, and raised revenue guidance. The analysis also weighs margin pressure, lower EPS guidance, and the ongoing shift away from legacy products.

Bristol-Myers Squibb Company (BMY) slips despite earnings beats
Bristol-Myers Squibb Company (BMY) slips 0.6% even after posting earnings beats, as investors weigh the latest results against broader market sentiment.
Want a deeper read on BMY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
fool.com · Nov 20
4 Dividend Stocks Wall Street Gave Up On With Balance Sheets Built to Recover
247wallst.com · Nov 20
3 Big Pharma Dividend Stocks Built for Retirement Income
247wallst.com · Nov 19
Vanguard’s Little-Known Value ETF Skips the Index and Goes Straight for the Cheapest Stocks
247wallst.com · Nov 19
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
businesswire.com · Nov 19
Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
zacks.com · Nov 18
Bristol-Myers Squibb: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 18
Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials
benzinga.com · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice